Department of Gynecological Oncology, Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin Key Laboratory of Human Development and Reproductive Regulation, 156 Nankai Third Road, Nankai, Tianjin, 300100, P. R. China.
J Ovarian Res. 2023 Jul 4;16(1):131. doi: 10.1186/s13048-023-01220-3.
Epithelial ovarian cancer (EOC) is often diagnosed at advanced stages with low survival rates. Protein tyrosine phosphatase receptor type M (PTPRM) is involved in cancer development and progression; however, its role in EOC remains unclear. In this study,we aimed to detect PTPRM expression in ovarian epithelial tumors, analyze its relationship with the clinicopathological features and survival prognosis of patients with EOC, and provide a theoretical basis for new targets for EOC treatment. Fifty-seven patients with EOC treated at our hospital between January 2012-January 2014 were included; along with 18 borderline and 30 benign epithelial ovarian tumors and 15 normal ovarian and uterine tube tissue samples from patients surgically treated at our hospital during the same period. PTPRM expression was immunohistochemically detected, and we analyzed its relationship with clinicopathological features and prognosis. Associations between PTPRM expression and survival prognosis of patients with EOC were analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA) and Kaplan-Meier Plotter databases.
PTPRM had the highest expression rates in normal ovarian and uterine tube tissues, followed by benign and borderline epithelial ovarian tumors; the lowest positive expression rate was observed in EOC tumors. PTPRM expression differed significantly among groups (P < 0.05). The positive PTPRM expression rate significantly decreased with age, progressing clinical stage, and tumor recurrence, and the larger the mass diameter, the higher the positive PTPRM expression rate. PTPRM expression was significantly lower in ovarian cancer compared with that in normal tissues in the GEPIA database (P < 0.05). The overall survival (OS) and disease-free survival(DFS) rates were higher in the PTPRM high-expression group, with statistically significant (P < 0.05) and insignificant (P > 0.05) differences, respectively. The OS rate of the high-expression group compared with the low-expression group in the Kaplan-Meier Plotter database was higher, although without statistical significance (P > 0.05), and progression-free survival(PFS) was higher with statistical significance (P < 0.05).
PTPRM expression was low in patients with EOC, and the PTPRM positive-expression rate significantly decreased with progressing stages of EOC and tumor recurrence, suggesting that PTPRM acts as a tumor suppressor in EOC progression. Negative PTPRM expression may predict poor clinical outcomes in patients with EOC.
上皮性卵巢癌（EOC）通常在晚期诊断，生存率低。蛋白酪氨酸磷酸酶受体 M（PTPRM）参与癌症的发生和发展；然而，其在 EOC 中的作用尚不清楚。在本研究中，我们旨在检测卵巢上皮性肿瘤中的 PTPRM 表达，分析其与 EOC 患者临床病理特征和生存预后的关系，为 EOC 治疗的新靶点提供理论依据。纳入 2012 年 1 月至 2014 年 1 月在我院治疗的 57 例 EOC 患者；同时纳入同期我院手术治疗的 18 例交界性和 30 例良性上皮性卵巢肿瘤以及 15 例正常卵巢和输卵管组织样本。采用免疫组织化学法检测 PTPRM 表达，并分析其与临床病理特征及预后的关系。采用基因表达谱分析交互式分析（GEPIA）和 Kaplan-Meier Plotter 数据库分析 EOC 患者 PTPRM 表达与生存预后的关系。
PTPRM 在正常卵巢和输卵管组织中的表达率最高，其次是良性和交界性上皮性卵巢肿瘤；EOC 肿瘤中的阳性表达率最低。各组间 PTPRM 表达差异有统计学意义（P<0.05）。PTPRM 阳性表达率随年龄、进展期临床分期和肿瘤复发而显著降低，肿块直径越大，PTPRM 阳性表达率越高。GEPIA 数据库中卵巢癌 PTPRM 表达明显低于正常组织（P<0.05）。PTPRM 高表达组患者的总生存（OS）和无病生存（DFS）率较高，差异有统计学意义（P<0.05）和无统计学意义（P>0.05）。Kaplan-Meier Plotter 数据库中，高表达组与低表达组的 OS 率较高，但差异无统计学意义（P>0.05），无进展生存（PFS）较高，差异有统计学意义（P<0.05）。
EOC 患者 PTPRM 表达降低，EOC 进展期和肿瘤复发时 PTPRM 阳性表达率显著降低，提示 PTPRM 在上皮性卵巢癌进展中起肿瘤抑制作用。PTPRM 阴性表达可能预示着 EOC 患者的临床结局不佳。
